<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05094869</url>
  </required_header>
  <id_info>
    <org_study_id>YYYXYJ-2021-182</org_study_id>
    <nct_id>NCT05094869</nct_id>
  </id_info>
  <brief_title>Prevention of HCC Using Mobile Phone Applications</brief_title>
  <official_title>Prevention of HCC Using Mobile Phone Applications: A Disease Management Project Based on CR-HepB Platform</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective cohort study is initiated to evaluate the compliance improvement to the&#xD;
      standardized follow-up and clinical management in the population of compensatory hepatitis B&#xD;
      cirrhosis with a mobile health application (APP). Patients were enrolled and divided into APP&#xD;
      self-management group (APP only ) and APP intelligent-management group (APP and online&#xD;
      interaction). The compliance to the standardized follow-up and clinical management (every six&#xD;
      months) under the two clinical management modes would be evaluated and compared with the&#xD;
      history data extracted from the platform of China Registry of Hepatitis B (CR-Hep B).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standardized follow-up and clinical management in the population of compensatory hepatitis B&#xD;
      cirrhosis is important in the prevention of liver cancer. In the clinical practice, follow-up&#xD;
      every six months are usually recommended. This prospective cohort study is initiated to&#xD;
      evaluate the compliance improvement to the standardized follow-up and clinical management&#xD;
      with a health management application (APP). 4000 patients who have registered on the platform&#xD;
      of China Registry of Hepatitis B (CR-Hep B) and been diagnosed as compensatory hepatitis B&#xD;
      cirrhosis would be recruited in the study. They were divided into two groups according to&#xD;
      whether they use the APP and whether there is online interaction between doctors and&#xD;
      patients:&#xD;
&#xD;
        1. APP self-management group (APP only, N=1000): Patients would register on the APP and&#xD;
           visit the clinics according to the routine practice and guidelines. During the study,&#xD;
           the APP would regularly send messages including the follow-up reminder (manually set up&#xD;
           by the patients on the APP), medication reminder, health education knowledge, etc.&#xD;
&#xD;
        2. APP intelligent-management group (APP and online interaction, N=3000): Patients would&#xD;
           register on the APP and visit the clinics according to the routine practice and&#xD;
           guidelines. During the study, the APP would regularly send messages including the&#xD;
           follow-up reminder (automatically set up by the APP), medication reminder, health&#xD;
           education knowledge, etc. The doctors will evaluate their disease progression every six&#xD;
           months through the APP and guide patients' clinical practice accordingly.&#xD;
&#xD;
      Patients in these two groups would be followed up for 2 years after enrollment. Besides,&#xD;
      history data of another 4000 Patients who have been on the platform of China Registry of&#xD;
      Hepatitis B (CR-Hep B) and been diagnosed as compensatory hepatitis B cirrhosis would be&#xD;
      extracted and serve as the control group (No APP and No online interaction, N=4000).&#xD;
&#xD;
      The compliance to the standardized follow-up and clinical management (every six months) under&#xD;
      the three clinical management modes would be evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient compliance to the standardized semi-annual follow-up</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Total follow-up times with the three clinical management modes. The event of follow-up is defined as self-reported clinic visit for liver cirrhosis assessment on the mobile phone application by patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Applicability of mobile phone application</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Applicability of mobile phone application is defined as cumulative minutes of APP use over the study period, which is recorded by APP itself.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical performance on HCC of the three clinical management modes</measure>
    <time_frame>0 to 2 years</time_frame>
    <description>Clinical performance on HCC is defined as the proportion of early stage HCC among all detected HCC. The event of HCC is measured with self-reported HCC and the stage on the mobile phone application by patients.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">8000</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>APP self-management group</arm_group_label>
    <description>Patients would register on the APP and visit the clinics according to the routine practice and guidelines. During the study, the APP would regularly send messages including the follow-up reminder (manually set up by the patients on the APP), medication reminder, health education knowledge, etc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APP intelligent-management group</arm_group_label>
    <description>Patients would register on the APP and visit the clinics according to the routine practice and guidelines. During the study, the APP would regularly send messages including the follow-up reminder (automatically set up by the APP), medication reminder, health education knowledge, etc. The doctors will evaluate their disease progression every six months through the APP and guide patients' clinical practice accordingly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>History data of another 4000 Patients who have been on the platform of China Registry of Hepatitis B (CR-Hep B) and been diagnosed as compensatory hepatitis B cirrhosis would be extracted and serve as the control group (No APP, no follow-up reminders, no online interaction).</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Use of mobile health application</intervention_name>
    <description>The APP would regularly send messages including the medication reminder, health education knowledge, etc.</description>
    <arm_group_label>APP intelligent-management group</arm_group_label>
    <arm_group_label>APP self-management group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Online interaction</intervention_name>
    <description>The patients would be able to upload their examination results in the APP and then the doctors will evaluate their disease progression every six months through the APP and guide patients' clinical practice accordingly.</description>
    <arm_group_label>APP intelligent-management group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Self follow-up reminders</intervention_name>
    <description>The APP would regularly send messages including the follow-up reminder (manually set up by the patient on the APP)</description>
    <arm_group_label>APP self-management group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Intelligent follow-up reminders</intervention_name>
    <description>The APP would regularly send messages including the follow-up reminder (automatically set up by the APP)</description>
    <arm_group_label>APP intelligent-management group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        4000 patients who have registered on the platform of China Registry of Hepatitis B (CR-Hep&#xD;
        B) and been diagnosed as compensatory hepatitis B cirrhosis would be recruited in the&#xD;
        study. Besides, history data of another 4000 Patients who have been on the platform of&#xD;
        China Registry of Hepatitis B (CR-Hep B) and been diagnosed as compensatory hepatitis B&#xD;
        cirrhosis would be extracted and serve as the control group.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Registered on the CR-HepB platform&#xD;
&#xD;
          -  Requiring or receiving antiviral therapy using nucleoside (acid) analogues&#xD;
             (recommended as the first-line therapy in the 2019 Chinese Guidelines for Chronic&#xD;
             Hepatitis B Prevention and Treatment )&#xD;
&#xD;
          -  Diagnosed as compensatory hepatitis B cirrhosis, with the diagnostic criteria fitting&#xD;
             any of the following criteria:&#xD;
&#xD;
               1. Diagnosis of Liver cirrhosis by histology;&#xD;
&#xD;
               2. Varicose veins in Esophageal and/or gastric fundus indicated by endoscopy;&#xD;
&#xD;
               3. Diagnosis of Liver cirrhosis by Imaging examination (abdominal ultrasound, CT,&#xD;
                  MRI) ;&#xD;
&#xD;
               4. Liver elasticity measurement &gt;12.0 kpa (ALT&lt;5Ã—ULN)&#xD;
&#xD;
               5. Platelet PLT lower than the lower limit of normal value, and Serum albumin (ALB)&#xD;
                  lower than 35 g/L or international standardized ratio (INR) &gt;1.3.&#xD;
&#xD;
          -  Completing the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  With any decompensated cirrhosis events, such as esophagogastric variceal rupture and&#xD;
             bleeding, ascites, and hepatic encephalopathy;&#xD;
&#xD;
          -  With any malignant tumor;&#xD;
&#xD;
          -  With serious illness on any vital organs and systems, including heart, lungs, kidneys,&#xD;
             and blood;&#xD;
&#xD;
          -  Unsuitable for participating the study deemed by researchers;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jidong Jia, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yuanyuan Kong, PhD</last_name>
    <phone>86-10-63139364</phone>
    <email>kongyy@ccmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jidong Jia, MD, PhD</last_name>
    <phone>86-13501378269</phone>
    <email>jia_jd@ccmu.edu.cn</email>
  </overall_contact_backup>
  <reference>
    <citation>Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, Li X, Wang L, Wang L, Liu Y, Liu J, Zhang M, Qi J, Yu S, Afshin A, Gakidou E, Glenn S, Krish VS, Miller-Petrie MK, Mountjoy-Venning WC, Mullany EC, Redford SB, Liu H, Naghavi M, Hay SI, Wang L, Murray CJL, Liang X. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019 Sep 28;394(10204):1145-1158. doi: 10.1016/S0140-6736(19)30427-1. Epub 2019 Jun 24. Erratum in: Lancet. 2020 Jul 4;396(10243):26.</citation>
    <PMID>31248666</PMID>
  </reference>
  <reference>
    <citation>Yang B, Zhang B, Xu Y, Wang W, Shen Y, Zhang A, Xu Z. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol. 1997;123(6):357-60.</citation>
    <PMID>9222303</PMID>
  </reference>
  <reference>
    <citation>Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014 Apr 1;11(4):e1001624. doi: 10.1371/journal.pmed.1001624. eCollection 2014 Apr.</citation>
    <PMID>24691105</PMID>
  </reference>
  <reference>
    <citation>Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, Roberts LR, Heimbach JK. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018 Aug;68(2):723-750. doi: 10.1002/hep.29913.</citation>
    <PMID>29624699</PMID>
  </reference>
  <reference>
    <citation>European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol. 2018 Jul;69(1):154-181. doi: 10.1016/j.jhep.2018.03.018. Epub 2018 Apr 5. Review.</citation>
    <PMID>29628280</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 22, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Jidong Jia</investigator_full_name>
    <investigator_title>Director of Liver Research Center</investigator_title>
  </responsible_party>
  <keyword>Compensatory hepatitis B cirrhosis</keyword>
  <keyword>Health management</keyword>
  <keyword>Mobile health application</keyword>
  <keyword>Compliance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

